Provider Briefing: The Budesonide Inhalation Shortage in 2026

The shortage of budesonide inhalation products — branded as Pulmicort by AstraZeneca — continues to affect clinical workflows and patient access in 2026. This briefing covers the current supply picture, prescribing implications, therapeutic alternatives, and tools to help your patients locate available stock.

Whether you're in pulmonology, allergy/immunology, pediatrics, or primary care, this update is designed to help you navigate the shortage efficiently and keep your patients on appropriate therapy.

Shortage Timeline

The budesonide inhalation supply disruption has evolved over the past two years:

• 2024: Initial reports of intermittent supply issues with budesonide inhalation suspension (generic Pulmicort Respules). Teva Pharmaceuticals, the primary generic supplier, began experiencing back orders on select presentations.
• 2025: AstraZeneca discontinued the Pulmicort Flexhaler 90 mcg, shifting demand to the 180 mcg strength and generic alternatives. Supply pressures intensified as seasonal respiratory illness increased demand.
• Early 2026: ASHP continues to list budesonide inhalation suspension as an active shortage. Teva has the 0.5 mg/2 mL formulation (5 vials/pouch) on back order with an estimated release of late March 2026. Other presentations remain on intermittent back order with supplies released as available.

Prescribing Implications

The shortage creates several practical challenges for prescribers:

Pediatric Patients Are Disproportionately Affected

Budesonide inhalation suspension (Pulmicort Respules) is one of the few inhaled corticosteroids approved for nebulization in children aged 12 months to 8 years. For this population, alternatives aren't as straightforward — switching to a metered-dose inhaler (MDI) requires age-appropriate spacer/mask use and may not be feasible for the youngest patients.

Prescription Transfers and Prior Authorization Delays

Patients who can't fill at their usual pharmacy may need prescriptions transferred or rewritten. If switching to a therapeutic alternative, new prior authorizations may be required by the patient's insurer, adding delays.

Risk of Treatment Gaps

The most significant clinical concern is patients simply going without their controller medication. Gaps in inhaled corticosteroid therapy can lead to increased airway inflammation, more frequent exacerbations, and potentially preventable ED visits or hospitalizations.

Current Availability Picture

As of March 2026, here's the practical availability landscape:

• Budesonide inhalation suspension (generic Respules): Intermittently available. Teva releasing stock as produced. Some pharmacies have supply; others do not. Availability varies significantly by region and distributor.
• Pulmicort Flexhaler 180 mcg: Available but supply inconsistent in some markets.
• Pulmicort Flexhaler 90 mcg: Discontinued. Not available.
• Generic budesonide DPI: Increasingly available as a lower-cost alternative to brand Flexhaler.

Recommend that patients use Medfinder for Providers or direct patients to medfinder.com to check real-time pharmacy stock in their area.

Cost and Access Considerations

The shortage has cost implications that may affect adherence:

• Brand-name Pulmicort Flexhaler: $200-$350+ without insurance
• Brand-name Pulmicort Respules: $350-$410+ without insurance
• Generic budesonide inhalation suspension: $45-$70 with discount cards
• Generic budesonide DPI: $45-$200 depending on pharmacy and coupon

Patients forced to fill at a different pharmacy or switch formulations may encounter unexpected cost increases. Consider discussing discount programs proactively:

• AstraZeneca co-pay savings: Available for commercially insured patients on brand-name products via azpatientsupport.com
• AZ&Me program: Patient assistance for uninsured/underinsured patients meeting income criteria
• Discount cards: GoodRx, SingleCare, and RxSaver can reduce generic budesonide costs to $45-$70

Therapeutic Alternatives and Substitution Guidance

When budesonide inhalation is unavailable, consider these therapeutic alternatives based on patient population:

For Adults and Adolescents (12+)

• Fluticasone propionate (Flovent HFA, Flovent Diskus, generics): Most widely available ICS alternative. Well-established efficacy and safety profile. Multiple formulations and strengths.
• Beclomethasone dipropionate (QVAR RediHaler): Extra-fine particle formulation. Breath-actuated device may benefit patients with poor inhaler technique.
• Mometasone furoate (Asmanex Twisthaler): Once-daily dosing option for appropriate patients. Also available as combination product with formoterol (Dulera).
• Ciclesonide (Alvesco): Prodrug with lower risk of oropharyngeal side effects. Useful for patients with history of thrush or dysphonia on other ICS agents.

For Pediatric Patients (Under 12)

• Fluticasone propionate HFA with spacer/mask: Can be used in children as young as 4. Requires proper spacer technique.
• Beclomethasone (QVAR RediHaler): Approved for ages 4+.
• Montelukast (Singulair): Not an ICS, but a leukotriene receptor antagonist that can serve as add-on or bridge therapy in mild persistent asthma while ICS supply is limited. Not a direct substitute for ICS in moderate-severe disease.

For Patients Requiring Nebulization

Budesonide inhalation suspension is the only widely available nebulized ICS. If unavailable for a young child who cannot use an MDI with spacer, consider:

• Transition to age-appropriate MDI with spacer/mask if developmentally feasible
• Compounding pharmacy may be an option in some cases (check state regulations)
• Short-term use of oral corticosteroids as bridge therapy in severe cases (with appropriate caution)

Tools and Resources for Your Practice

• Medfinder for Providers: Real-time pharmacy stock checker. Direct patients here or use it to identify pharmacies with available supply before writing a prescription.
• ASHP Drug Shortage Database: ashp.org/drug-shortages — monitor official shortage status and manufacturer updates
• FDA Drug Shortage Database: fda.gov/drugs/drug-safety-and-availability/drug-shortages

Looking Ahead

Teva's estimated late-March 2026 resupply date offers some near-term optimism, but full resolution of the budesonide inhalation shortage will depend on sustained manufacturing output and demand stabilization. The discontinuation of Pulmicort Flexhaler 90 mcg is permanent, meaning the market has permanently lost one supply source.

Proactive communication with patients — explaining the shortage, discussing alternatives early, and pointing them to tools like Medfinder — can minimize treatment gaps and reduce the volume of reactive calls your office handles.

Final Thoughts

The budesonide inhalation shortage requires a proactive approach from prescribers. Know your alternatives, anticipate patient questions about cost and availability, and leverage real-time tools to keep patients on therapy. The shortage will eventually resolve, but your patients need solutions now.

For related provider resources, see our guide on how to help patients find Pulmicort in stock and the provider's guide to helping patients save money on Pulmicort.